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Historically, pregnant women have been excluded from the majority of drug and vaccine 
trials, a practice that has been widely criticized by the scientific community 1-3. The result is 
that pregnant women are routinely denied beneficial, sometimes potentially life-saving, 
therapeutic and preventive measures, or receive them well after their non-pregnant peers. 
Data about safety and efficacy in pregnancy subsequently accumulate adventitiously as 
women receive the drug or vaccine not realising that they were pregnant, or fall pregnant 
soon after receiving the therapy. In the absence of any significant adverse effects, eventually 
sufficient confidence is established (either as ‘evidence of no harm,’ or, more frequently, as 
‘no evidence of harm’) for a formal trial to be considered or alternatively, the use of the 
intervention in pregnancy simply slips into routine practice.  
 
This pattern has been repeated with COVID-19 vaccines; pregnant women were excluded 
from the initial trials. Only a small number of women who were unknowingly pregnant or fell 
pregnant soon after vaccination have been included – this small cohort is currently being 
followed up as part of the original trials 4,5 Due to lack of evidence around the safety of these 
vaccines in pregnancy, international societies have tended to take a cautious approach, 
recommending that vaccination of pregnant women should be evaluated on a case-by-case 
basis. The Society of Obstetricians and Gynaecologists of Canada and the International 
Federation of Gynecology and Obstetrics are notable exceptions as early endorsers of 
unrestricted vaccination in pregnancy 6,7. In the United Kingdom (UK), the Royal College of 
Obstetricians and Gynaecologists (RCOG) suggests that pregnant women at very high risk 
should be considered eligible for vaccination 8-10; these criteria are under constant review 
and were recently updated on 24th of February. Proposed risk factors are derived from 
literature relating specifically to pregnant women with COVID-19 and also extrapolated from 
non-pregnant women with COVID-19. They consist primarily of chronic diseases or 
immunosuppressive conditions, as well as women at high risk of exposure to the virus 
(Table 1). It must also be acknowledged that women can experience severe COVID-19 even 
in the absence of any of these risk factors11. The Royal Australian and New Zealand College 
of Obstetricians and Gynaecologists have taken a stance similar to the RCOG12.  The 
American College of Obstetricians and Gynecologists (ACOG) recommends that ‘COVID-19 
vaccines should not be withheld from pregnant women who meet criteria for vaccination 
based on ACIP (Advisory Committee on Immunization Practices) recommended priority 
groups’. Here we summarize the available evidence to support counseling for women 
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Risks of COVID-19 in pregnant women and potential benefits of vaccination 
 
Most pregnant women with COVID-19 will remain asymptomatic or have a mild illness. 
Fortunately, severe disease and death are rare outcomes. In the UK, for example, the 
maternal mortality rate associated with COVID-19 is 2.2 per 100,000 maternities 13-16. 
Pregnant women hospitalised with COVID-19, however, are more likely to be admitted to the 
Intensive Care Unit (ICU) compared to non-pregnant women with the infection, although it is 
unclear whether this represents more serious illness or a lower threshold for ICU admission 
14. Despite this, according to a large systematic review 14, pregnant women do not appear to 
be at greater risk of death. Some studies from both high and low incomes settings, however, 
report increased maternal mortality15,17. Summary findings should be contextualised if used 
during patient counseling.  Compared with pregnant women without COVID-19, those with 
symptomatic COVID are at increased risk of adverse pregnancy outcomes, including 
maternal ICU admission, iatrogenic preterm birth, preeclampsia like symptoms, Caesarean 
section and death13-15. Reports of stillbirth in the literature are very heterogeneous; rates 
seem to be increased in low to middle-income countries while there was no significant 
increase in high-income countries18,19. COVID-19 has other indirect effects on maternal and 
fetal outcomes, such as increased maternal mental distress and intimate partner 
violence19,20.  
 
The risk of severe adverse outcomes (e.g., ICU admission, maternal death, or stillbirth) will 
be modified by individual and societal risk factors, and the availability and performance of 
healthcare in their setting19. Nevertheless, it seems reasonable to counsel pregnant women 
with obesity, advanced age, or significant chronic conditions (Table 1) that they are at 
increased risk of severe COVID-19 and, therefore, more likely to benefit from vaccination in 
terms of protection from life-threatening COVID-19 (Table 2). Observational studies indicate 
that postnatal transmission of SARS-CoV-2 from mother to baby is rare, and continued 
breastfeeding appears to be safe21-23. The minimal postnatal transmission risk will probably 
be even lower in vaccinated mothers. The presence of anti-SARS-CoV-2 IgG has been 
reported in the neonate of a vaccinated mother, but it is not yet possible to say what impact 
maternal vaccination will have on neonatal protection against infection after birth24,25. Other 
secondary adverse effects of COVID-19 include mother-infant separation in some settings, 
increased Caesarean section and iatrogenic preterm birth. The incidence of these adverse 
effects is likely to be reduced by vaccination too and women should be counselled about the 
probable additional benefits of vaccination over and above protection from severe disease 
(Table 2).  
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Available vaccines and their safety profiles 
 
Four different types of COVID-19 vaccine are currently available: mRNA, viral vector, 
inactivated virus, and recombinant antigen (Table 3). As yet, only three COVID-19 vaccines, 
two mRNA and one adenoviral vector, are approved for emergency use by both the US 
Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the 
Medicines and Healthcare Products Regulatory Agency (MHRA), namely mRNA-1273 
(Moderna Therapeutics, Cambridge, MA, USA), BNT162b2 (BioNTech, Fosun Pharma, 
Pfizer, Mainz, Germany) and Ad.26.COV2 (Janssen Pharmaceutica, Beerse, Belgium). The 
Oxford-AstraZeneca (AZD1222), another viral vector vaccine approved by the EMA, is 
commonly used in the UK. The two FDA approved mRNA vaccines were shown to elicit a 
very strong immune response and protection against severe COVID-194,26. Unpublished 
mRNA vaccine (mRNA-1273) data from a study of pregnant rats identified no safety 
concerns regarding malformations or embryotoxicity27. Trials of both vaccines excluded 
pregnant women. Initial reports from regulatory bodies, such as the EMA, show that a small 
number of women in the trial were pregnant at the time of vaccination; safety data from 
these pregnancies are still pending but, as yet, no significant adverse effects have been 
observed28,29. More recently,  Dr Anthony Fauci, Chief Medical Advisor to US President 
Biden, stated that more than 20,000 pregnant women have received an mRNA vaccine and 
to date there have been no concerning ‘red flags’30,31. These as yet unpublished data 
illustrate that many pregnant women are willing to be vaccinated when their autonomy is 
respected and they have the opportunity to weigh their own personal risks and benefits. 
These preliminary safety data are reassuring and their publication is eagerly awaited.  
 
Although mRNA vaccines have never previously been deployed on such a scale, they are 
not new. mRNA vaccines are not live virus vaccines and do not use an adjuvant to increase 
vaccine efficacy. The mRNA does not enter the cell nucleus and cannot alter the human 
genome in vaccinees. Animal studies have demonstrated the safety, efficacy, and potential 
benefit of mRNA vaccines in pregnant women, benefits which may extend beyond simply 
protecting the mother from pathogens. Zika virus is a zoonotic pathogen, like coronavirus, 
and is capable of intrauterine infection. In 2018, Richner et al. published a report describing 
the efficacy of an mRNA vaccine against Zika virus in pregnant mice32. Following 
vaccination, pregnant mice were infected with live Zika virus; pups born to vaccinated dams 
showed no viral load in their brain tissue. Furthermore, the viral load was at or below the 
detection threshold in placental samples. The authors concluded that the mRNA vaccine 
was safe in pregnant mice and that it prevented vertical transmission of Zika virus. The 
principles of this vaccination technology should also apply to COVID-19 vaccines, and 
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provides generic reassurance around the use of mRNA vaccines in pregnancy. Furthermore, 
vaccination is likely to protect not only the pregnant woman but also the fetus and neonate. 
With regards to COVID-19 vaccines, for example, a recent case report demonstrated 
transplacental transmission of antibodies against the spike protein following vaccination of 
the mother24,25. Efficient transplacental transfer of SARS-CoV-2 IgG antibodies in the 
majority of seropositive pregnant women after natural infection has also been shown.33. The 
presence of neutralizing antibodies in the fetal/neonatal circulation is potentially an added 
benefit of vaccination for protection of the baby, in both fetal and neonatal life, against 
COVID-19.  
 
Three adenoviral vaccines Oxford-AstraZeneca AZD1222, Janssen Ad.26.COV2 and Gam-
COVID-Vac, (also known as Sputnik V) have recently reported Phase 3 trial data showing 
high levels of efficacy against COVID-19, especially against severe disease and 
hospitalization5,34,35. As with the mRNA vaccines there are limited data on the safety of 
adenovirus vector vaccines in pregnancy, though adenovirus vector-based Zika vaccines 
have been tested in pregnant mice without safety concerns36. These vaccines do not contain 
live virus and neither the COVID protein nor the adenovirus vector replicates in humans, and 
are eliminated from the tissues following injection.  
 
Two inactivated virus vaccines from China (BBIBP-CorV, Beijing Institute of Biological 
Products, China; CoronaVac, Sinovac Life Sciences, Beijing, China) and one from India 
(Bharat Biotech) are commercially available. Varying efficacy rates for preventing 
symptomatic infection have been reported37-41. However, they had similarly high protection 
against severe COVID-19 and death. Inactivated virus vaccines are considered safe in 
pregnancy, though the aluminium oxide adjuvant used in these vaccines do not have a 
designated FDA safety category due to the lack of data42,43. However, alum adjuvants are 
used in many vaccines, including Hepatitis B, DTaP and human papillomavirus (HPV). 
Inadvertent vaccination with HPV vaccines during pregnancy has not been associated with 
any safety concerns 44. A similar safety profile was observed with respiratory syncytial virus 
vaccine, which also uses alum adjuvant45.  
 
There is one recombinant antigen vaccine (Novavax) that showed high efficacy against 
symptomatic SARS-CoV-2 infection46. The antigens produced by recombinant technology 
are coupled with a saponin-based proprietary adjuvant in order to elicit an immune 
response. Recombinant vaccines are considered safe in pregnancy due to their non-
replicating nature. However, the saponin-based proprietary adjuvant used in this vaccine 
lacks safety data in pregnant women.  
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Ongoing trials and pending safety data 
 
Pregnancy trials of BNT162b2 (BioNTech, Fosun Pharma, Pfizer) and Ad.26.COV2 
(Janssen Pharmaceutica) are due to start soon. However, enrolment to prospective trials is 
threatened by the current global demand for vaccines, which will only increase with time. 
Worldwide, pregnant women are already choosing to be vaccinated against COVID-19, and 
safety data accumulating in official registries are likely to play a key role for expectant 
mothers considering vaccination. It is essential that countries establish national registries of 
pregnant women receiving the different types of COVID-19 vaccine as a matter of urgency; 
where possible, international registries should be developed 47,47. Monitoring pregnancy, 
foetal and neonatal outcomes in vaccinated women and comparing them with those in 
unvaccinated pregnant women must be a priority.  
 
Moreover, the ethics of enrolling pregnant women into placebo controlled trials is 
increasingly questionable, at a time when more and more pregnant women, particularly 
those with risk factors for severe COVID-19, are already receiving the vaccine. These 
vaccines are likely to deliver similar benefit to pregnant women as to non-pregnant 
individuals, and are likely to be safe. Withholding such a vaccine from prospective mothers 
who understand and accept the uncertainty of available preventive measures, while offering 
them enrolment into a placebo-controlled trial, might prove ethically challenging. 
Nevertheless, there are a number of advantages in recruiting pregnant women into trials in 
which they receive a licensed COVID-19 vaccine. This includes addressing questions 
around optimal timing of vaccinations, number of doses, dose intervals and need for 
boosters in future pregnancies. In the meantime, animal studies should be rapidly 
undertaken to provide safety information about the current unknowns of COVID-19 vaccines, 
such as transplacental passage of mRNA containing lipids or the safety of adjuvants and 
adenoviral vectors. There is an urgent need to focus and allocate more resources to 





Pregnant women should be provided with a balanced and clear assessment of their risk of 
COVID-19 in pregnancy, taking into account their individual circumstances, local practices 
and available evidence from similar healthcare settings. In addition, they should be 
counselled with a balanced summary of the potential direct and indirect benefits of COVID-
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19 vaccines, while acknowledging the limited safety data. Whilst these vaccines have not yet 
been trialled in pregnancy, they are being offered to pregnant women with risk factors for 
severe COVID-19 during the national rollout of vaccine programmes in the UK. These 
vaccines are also currently offered to pregnant women with a high risk of exposure to SARS-
CoV-2, including health and care workers. In the UK, the MHRA is receiving regular 
feedback from the vaccination programme and any concerns are met with approriate action. 
So far, no safety concerns in vaccinated pregnant women have been reported in either the 
UK or the US. We believe that COVID-19 vaccination should not be withheld from pregnant 
women who have received adequate counselling and understand the uncertainties, minimal 
potential harms, and likely benefits of these vaccines. We also encourage further research to 
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Table 1. Risk groups for pregnant women, for whom vaccination should be considered 
according to the Royal College of Obstetricians and Gynaecologists (RCOG). 
 
Risk factors for serious COVID-19 
• Underlying medical conditions such as immune conditions, diabetes, high blood 
pressure, heart disease or asthma 
• Overweight 
• Age over 35  
• Third trimester pregnancy (over 28 weeks) 
Risk factors for catching COVID-19 
• Health or social care worker in the same household 
• Increased rate of COVID-19 infections in the woman’s community 
• Frequent contact with people outside the home 
• Not being able to comply with social distancing 
• Crowded household 
• Black, Asian or minority ethnicity background 
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Table 2. Direct and indirect detrimental effects of COVID-19 on pregnant women and the 
potential effect of vaccination 
 




Rare  COVID-19, direct  Prevention 
Mechanical ventilation 
or ECMO 
Rare  COVID-19, direct Prevention 
Maternal death Rare  COVID-19, direct Prevention 
Iatrogenic preterm birth Common COVID-19, indirect Reduction 
Caesarean section Common COVID-19, indirect Reduction 
Stillbirth Rare  Severe COVID-19, reduced 




Common Reduced healthcare access, 










Uncommon Perceived risk of transmission 
or COVID-19 treatment 
incompatible with nursing 
Reduction 
Vertical transmission Rare COVID-19, direct Reduction/Prevention 
 
ICU: intensive care unit; ECMO: extracorporeal membrane oxygenation 
This article is protected by copyright. All rights reserved.
Table 3. Available vaccines with available phase III trial results. All listed vaccines have very high protection rates against serious and life-
threatening COVID-19 infection. 
 
Vaccine Technology Property Direct safety data Indirect safety data from 
vaccines using similar 
technology 
Unknowns and theoretical 
safety concerns 
mRNA-1273 mRNA Non-replicating Tested on pregnant mice: 
no signs of embryonal, 
fetal or postnatal 
developmental problems 
mRNA based ZIKA virus 
vaccine used in pregnant 
mice 
 
Transplacental passage of 
mRNA containing lipids 
BNT162b2 mRNA Non-replicating NA 
AZD1222 Viral vector Non-replicating NA Adenovirus based ZIKA 




Ad.26.COV2 Viral vector Non-replicating NA 
Gam-
COVID-Vac 
Viral vector Non-replicating NA 
BBIBP-CorV Inactivated virus 
with aluminium 
hydroxide adjuvant 
Non-replicating NA Inactivated vaccines are 
considered safe during 
pregnancy. Alum adjuvant 
has been used in vaccines 
that are considered safe 
during pregnancy (HPV, 
RSV) 
Alum adjuvant 
CoronaVac Inactivated virus 
with aluminium 
hydroxide adjuvant 
Non-replicating NA Alum adjuvant 
Novavax Recombinant 
antigen with saponin 
based adjuvant 
Non-replicating NA Recombinant vaccines are 
considered safe during 
pregnancy.  
Saponin based proprietary 
adjuvant 
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